First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

10/07/2018
MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program...
15/06/2018
MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in...
15/06/2018
MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in...
12/06/2018
New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab...
17/05/2018
Annual General Meeting of MorphoSys AG Elects New Supervisory Board Members
17/05/2018
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood...
02/05/2018
MorphoSys AG Reports First Quarter 2018 Results
01/05/2018
MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical...
26/04/2018
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea
23/04/2018
MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and...

June 20, 2018
Webcast JMP Securities Life Sciences Conference

Full details

 

 

 

 

Simon Moroney, CEO
on Strategy and Goals